ProBio is a New Jersey-based fully integrated end-to-end contract development and manufacturing organization (CDMO) that focuses on enabling biotech and pharmaceutical companies to accelerate novel drug development and supply for clinical trials through to commercialization.
ProBio develops technology-driven proprietary platform processes to support the full lifecycle of biologics drug development and manufacturing of next generation medicine: biologics and advanced therapies. Our technical and operational expertise spans the discovery, development, and drug substance or drug product (DS/DP) manufacturing of antibody-based therapeutics, including monoclonal, bispecific, and multi-specific antibodies, recombinant proteins, plasmid DNA, viral vectors, mRNA, and vaccines. Additionally, we provide specialized integrated services in process development, bioanalytical development, formulation and in vitro/in vivo pharmacology.